文献速递瓣膜病与结构性心脏病

抗炎药物对恶性心包积液患者临床结局的影响

Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该研究纳入445例接受超声引导下心包穿刺引流的恶性心包积液活动性癌症患者,评估穿刺后使用抗炎药物对长期结局的影响。中位随访2年,秋水仙碱组复合终点事件(全因死亡、再穿刺或心包开窗)风险显著低于非秋水仙碱组(aHR 0.65,95%CI 0.49-0.87,p=0.003),全因死亡风险亦显著降低(aHR 0.60,95%CI 0.45-0.81,p=0.001)。

要点

  • 恶性心包积液患者穿刺引流后使用秋水仙碱与复合终点事件风险降低独立相关。
  • 秋水仙碱组全因死亡风险显著低于非秋水仙碱组。
  • 倾向性评分匹配后秋水仙碱的获益结论保持一致。

核心结论

  • 在活动性癌症合并恶性心包积液患者中,成功心包穿刺引流后接受秋水仙碱治疗与复合终点事件及全因死亡风险显著降低相关。

主要发现

  • 操作成功率为97.0%,发生1例操作相关死亡。
  • 2年随访期间,26.1%的患者出现复发性心包积液,46.0%出现缩窄性心包炎。
  • 秋水仙碱治疗组复合终点事件风险显著低于非秋水仙碱组(aHR 0.65;95%CI 0.49-0.87;p=0.003)。
  • 秋水仙碱治疗组全因死亡风险显著低于非秋水仙碱组(aHR 0.60;95%CI 0.45-0.81;p=0.001)。
  • 倾向性评分匹配后,穿刺后使用秋水仙碱仍与较低的复合终点事件风险相关(aHR 0.55;95%CI 0.37-0.82;p=0.003)。

关键数值与推荐

  • 秋水仙碱给药方案为0.6 mg口服,每日两次,持续2个月。
  • 主要终点定义为全因死亡与因复发性心包积液行再穿刺或心包开窗手术的复合终点。

临床怎么用

  • 对于活动性癌症合并恶性心包积液且成功行心包穿刺引流的患者,可考虑在穿刺后使用秋水仙碱(0.6 mg每日两次,持续2个月)以改善长期临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pericardiocentesis (PCC) with extended catheter drainage has become a relatively safe procedure to control pericardial effusion (PE), but little is known about long-term outcomes after PCC in malignant PE. OBJECTIVES: This study evaluated the effects of anti-inflammatory agents on long-term outcomes after effective drainage of PE in active cancer patients. METHODS: From May 2007 to December 2018, 445 patients with malignant PE who underwent echocardiography-guided PCC were enrolled. Clinical, laboratory, echocardiographic and procedural findings, and clinical outcome data were collected. Use of anti-inflammatory agents including colchicine, nonsteroidal anti-inflammatory drugs, or steroids after PCC was also analyzed. Colchicine was administered in a dose of 0.6 mg orally, twice a day for 2 months. The primary outcome was defined as a composite of all-cause death and re-PCC or pericardial window operation due to recurred PE. RESULTS: The procedure was successful in 97.0% of the cases, with 1 procedure-related death. During the follow-up of 2 years, 26.1% of patients developed recurrent PE, and 46.0% developed constrictive pericarditis. The colchicine treatment group showed a significantly lower risk of composite events (adjusted hazard ratio [aHR]: 0.65; 95% confidence interval [CI]: 0.49 to 0.87; p = 0.003) as well as all-cause death (aHR: 0.60; 95% CI: 0.45 to 0.81; p = 0.001) than did the noncolchicine group. On propensity score matching, colchicine after PCC was consistently associated with a lower composite events (aHR: 0.55; 95% CI: 0.37 to 0.82; p = 0.003). CONCLUSIONS: In cancer patients with malignant PE, PCC with extended drainage can be an appropriate therapeutic option and shows low complication rate. Patients receiving colchicine after successful PCC showed significant improvement in clinical outcome.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kim SR, Kim EK, Cho J, et al. Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients With Malignant Pericardial Effusion. J Am Coll Cardiol. 2020. PMID: 32972532. doi:10.1016/j.jacc.2020.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。